17 active not recruiting. 17 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Active not recruiting 17 |
| Phase 2 | 4 | Active not recruiting 4 |
Follow Stomach Diseases: new trials by email Literature Review of Stomach Diseases trials Research Report on Stomach Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE) Conversion Surgery, Systemic Therapy/Standard of Care - Gastric Cancer Stage IV, Peritoneal Metastasis | Phase 2 / Phase 3 | Active not recruiting | National University Hospital, Singapore | 300 | 2026-02-21 | 2026-05-14 |
| Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer Tislelizumab + SOX Chemotherapy, SOX Chemotherapy - Gastric Cancer Stage III | Phase 3 | Active not recruiting | The First Affiliated Hospital with Nanjing Medical University | 416 | 2024-12-01 | 2025-07-01 |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 AZD0901, Ramucirumab+ paclitaxel, Paclitaxel - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | Active not recruiting | AstraZeneca | 594 | 2024-03-04 | 2026-10-15 |
| A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer RC48-ADC（2.5mg/kg）, Trastuzumab, Toripalimab - Gastric Cancer | Phase 2 / Phase 3 | Active not recruiting | RemeGen Co., Ltd. | 201 | 2023-08-04 | 2025-09-29 |
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) Evorpacept (ALX148), Trastuzumab, Ramucirumab - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | ALX Oncology Inc. | 127 | 2022-01-15 | 2025-08-07 |
| A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers Zanidatamab, Tislelizumab, Trastuzumab - Gastric Neoplasms, Gastroesophageal Adenocarcinoma | Phase 3 | Active not recruiting | Jazz Pharmaceuticals | 920 | 2021-12-02 | 2026-10-20 |
| A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) ONO-4538, Ipilimumab, Oxaliplatin - Gastric Cancer | Phase 3 | Active not recruiting | Ono Pharmaceutical Co., Ltd. | 626 | 2021-11-05 | 2026-06-25 |
| Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) Trastuzumab deruxtecan, Ramucirumab, Paclitaxel - Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Active not recruiting | Daiichi Sankyo | 490 | 2021-05-21 | 2026-05-27 |
| A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). zolbetuximab, oxaliplatin, capecitabine - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Phase 3 | Active not recruiting | Astellas Pharma Global Development, Inc. | 507 | 2018-11-28 | 2026-09-28 |
| A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer. zolbetuximab, placebo, oxaliplatin - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Phase 3 | Active not recruiting | Astellas Pharma Global Development, Inc. | 565 | 2018-06-21 | 2026-10-20 |
| Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. Cytoreductive surgery + Gastrecomy, Hyperthermic Intraperitoneal Chemotherapy (HIPEC) - Stomach Neoplasm, Peritoneal Carcinomatosis | Phase 3 | Active not recruiting | The Netherlands Cancer Institute | 102 | 2017-10-01 | 2025-07-17 |
| Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population 10-day bismuth-based quadruple therapy, Placebo - Gastric Cancer, Helicobacter Pylori Infection | Phase 3 | Active not recruiting | National Cancer Center, Korea | 5224 | 2014-06-01 | 2024-12-27 |
| Domperidone in Treating Patients With Gastrointestinal Disorders Domperidone, Questionnaire Administration - Digestive System Disorder, Dyspepsia | Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 96 | 2012-10-23 | 2026-09-24 |
| Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy IGIMRT using a single dose of 24 Gy, IGIMRT 27 Gy in 3 fractions - Melanoma, Ovarian Cancer | Phase 3 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 220 | 2010-10-01 | 2025-11-04 |
| Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel, Preoperative chemoradiotherapy, Gastric resection - Gastric Cancer | Phase 2 / Phase 3 | Active not recruiting | Australasian Gastro-Intestinal Trials Group | 574 | 2009-09-01 | 2025-03-04 |
| Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication Placebo, LAC triple therapy - Gastric Cancer, Helicobacter Pylori Infection | Phase 3 | Active not recruiting | National Cancer Center, Korea | 1838 | 2004-11-01 | 2023-11-09 |
| Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD 7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin, Placebo, Omeprazole or Rabeprazole, Clarithromycin - Helicobacter Pylori Infection, Early Gastric Cancer | Phase 3 | Active not recruiting | National Cancer Center, Korea | 470 | 2003-06-01 | 2023-11-09 |
Stomach Neoplasms (15) · Adenocarcinoma (3) · Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Atrophy (1) · Digestive System Diseases (1) · Dyspepsia (1) · Esophageal Neoplasms (1) · Esophagitis (1) · Gastroesophageal Reflux (1) · Gastroparesis (1) · Heartburn (1) · Melanoma (1) · Nausea (1) · Ovarian Neoplasms (1)
Gastrointestinal Diseases (17) · Digestive System Diseases (16) · Neoplasms by Site (16) · Digestive System Neoplasms (15) · Gastrointestinal Neoplasms (15) · Neoplasms (14) · Neoplasms by Histologic Type (4) · Carcinoma (3) · Neoplasms, Glandular and Epithelial (3) · Esophageal Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Abdominal Neoplasms (1) · Adnexal Diseases (1) · Deglutition Disorders (1)
Oxaliplatin (6) · Capecitabine (5) · Fluorouracil (3) · Paclitaxel (3) · Trastuzumab (3) · Cisplatin (2) · Docetaxel (2) · Leucovorin (2) · Ramucirumab (2) · tislelizumab (2) · zolbetuximab (2) · ALX148 (1) · Amoxicillin (1) · Clarithromycin (1) · Conversion to Open Surgery (1)
National Cancer Center, Korea (3) · Astellas Pharma Global Development, Inc. (2) · ALX Oncology Inc. (1) · AstraZeneca (1) · Australasian Gastro-Intestinal Trials Group (1) · Daiichi Sankyo (1) · Jazz Pharmaceuticals (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National University Hospital, Singapore (1) · Ono Pharmaceutical Co., Ltd. (1) · RemeGen Co., Ltd. (1) · The First Affiliated Hospital with Nanjing Medical University (1) · The Netherlands Cancer Institute (1)
South Korea (10) · China (7) · Japan (7) · Spain (7) · Taiwan (7) · France (6) · Italy (6) · United Kingdom (6) · United States (6) · Belgium (5) · Canada (5) · Germany (5) · Australia (4) · Brazil (4) · Poland (4)
Il Ju Choi, M.D., Ph.D. (2) · Il Ju Choi, MD, PhD (1) · Johanna van Sandick, MD, PHD (1) · Mehnaz Shafi (1) · Na Su, PhD (1) · Project Leader (1) · Rolando Herrero, M.D.,Ph.D (1) · Trevor Leong, MBBS, MD (1) · Yoshiya Yamada, MD (1)
PMID 40341124, PMID 38861294, PMID 40680855, PMID 42095986, PMID 29562147, PMID 30480549, PMID 31060544, PMID 31995688, PMID 33422612, PMID 36000541, PMID 37068504, PMID 37524953, PMID 37916797, PMID 39232496, PMID 39282905, PMID 40454632, PMID 41324998, PMID 42202319, PMID 42419336, PMID 42786305
2023 (2), 2015 (1), 2017 (1), 2018 (1)